Alligator appoints Theradex Oncology as clinical CRO for ATOR-1015 phase I study

This article was originally published here

Published 26 January 2018

Alligator Bioscience has appointed Theradex Oncology has appointed as CRO for the planned phase I study of ATOR-1015 for the treatment of metastatic cancer.

The study is expected to commence in the second half of 2018.

The upcoming clinical phase I study with ATOR-1015 is a first-in-human dose escalation study in patients with metastatic cancer. The study will be conducted at five sites in Sweden and Denmark.

“Engaging Theradex is a key step towards starting our clinical phase I study with ATOR-1015 later this year”, said Per Norlén, CEO of Alligator Bioscience.

“We have worked previously with Theradex on the ADC-1013 clinical phase I trial and, based on their robust delivery and extensive expertise in clinical oncology research, we are confident in their ability to assist us in executing high-quality studies and we look forward to continuing our successful collaboration”.

ATOR-1015 is a first-in-class bispecific antibody that targets CTLA-4 and OX40 and was created with Alligator’s unique bispecific technology.

Alligator has advanced ATOR-1015 through preclinical development and is now preparing for the start of a clinical phase I study. Production of clinical trial material has already been completed and the final clinical trial authorization (“CTA”) enabling activities required for study initiation will be completed in H1 2018.

Source: Company Press Release

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply